Disclosures for "Congenital Mydriasis and Retinal Arteriolar Tortuosity: Biomarkers of Disease for MSMDS ACTA2 Arg179 Pathogenic Variants"
-
Ms. Lynch has nothing to disclose.
-
Ms. Zhang has nothing to disclose.
-
Dr. Tambala has nothing to disclose.
-
Dr. Hospital has nothing to disclose.
-
Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alcon. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regneron. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dutch Ophthalmic.
-
Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Minoryx Pharmaceuticals. Dr. Musolino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Altas Venture Capital. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for IONIS Pharmaceuticals . Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vertex. The institution of Dr. Musolino has received research support from National Institute of Health-NINDS-R01. The institution of Dr. Musolino has received research support from Angea Biotherapeutics. The institution of Dr. Musolino has received research support from Minoryx Pharmaceuticals. Dr. Musolino has received publishing royalties from a publication relating to health care.